Tdap Vaccination in Pregnancy: Effectiveness, Timing, and Safety

Effectiveness of Maternal Tdap

Administering Tdap between 27 – 36 weeks gestation provides 80‑91 % effectiveness in preventing pertussis in infants younger than 2 months, protecting the newborn before its own vaccine series begins. 1
Infants born to vaccinated mothers have significantly higher pertussis‑specific antibody concentrations at birth and at two months of age compared with those whose mothers were unvaccinated. 1
Pertussis antibodies wane substantially within the first year after maternal vaccination, so protection does not persist across successive pregnancies. 1
Women who receive Tdap before or early in pregnancy often have low antibody levels at delivery, insufficient to confer infant protection. 2

The optimal window for Tdap administration is 27 – 36 weeks gestation, which maximizes maternal antibody production and passive transfer to the fetus. 3
Vaccinating earlier in this window (27 – 32 weeks, especially 27 – 30 weeks) yields higher cord‑blood antibody levels than vaccination after 32 weeks. 1
At least 2 weeks after vaccination are required for antibodies to reach peak levels and be transferred across the placenta. 2
Placental transport of IgG antibodies is minimal before 30 weeks gestation, reinforcing the need to vaccinate within the 27‑36 week period. 2

Large‑scale surveillance (including the Vaccine Safety Datalink and VAERS) has identified no safety signals for Tdap administered during pregnancy. 2
Worldwide use of tetanus‑toxoid‑containing vaccines in pregnant women has not been associated with clinically significant severe adverse events. 2
Observational data from over 16 000 vaccinated pregnant women show no increased risk of major maternal or infant outcomes, including preterm delivery, low birth weight, stillbirth, or congenital anomalies. 2

Infants of vaccinated mothers exhibit a modest reduction (approximately 7‑48 %) in antibody responses to their own DTaP series after the third dose. 1
After the fourth DTaP dose, antibody levels in these infants become comparable to those of infants whose mothers were unvaccinated. 1
The clinical significance of this blunting is uncertain, because definitive protective antibody thresholds for pertussis have not been established. 1
The theoretical blunting is outweighed by the proven benefit of preventing pertussis during the first two months of life, when infants are most vulnerable. 4

Tdap should be given in every pregnancy, regardless of prior receipt in a previous pregnancy. 1
Do not delay vaccination beyond 36 weeks gestation, as sufficient time is needed for antibody development and transfer. 2
Do not substitute postpartum vaccination for prenatal vaccination, because postpartum dosing does not protect the infant during the high‑risk early period. 2
Do not withhold Tdap because the mother received it within the past year; repeat dosing during each pregnancy is recommended to ensure optimal infant protection. 1

The Centers for Disease Control and Prevention recommends that Tdap should ideally be administered between 27-36 weeks gestation to maximize maternal antibody response and passive antibody transfer to the infant 5, 6, 7
Vaccinating earlier within this window (27-30 weeks) appears to produce higher antibody concentrations in cord blood compared to later administration 8, 9
After Tdap administration, a minimum of 2 weeks is required to mount a maximal immune response to the vaccine antigens 5, 10
Active transport of maternal immunoglobulin G does not substantially occur before 30 weeks of gestation 5, 9
Maternal antibodies wane quickly; women immunized during the first or second trimester have shown low antibody levels at term 5, 7

Maternal Tdap vaccination during pregnancy from 27-36 weeks gestation is 80-91% effective in preventing infant pertussis 9
Among infants whose mothers received Tdap during pregnancy, those born to mothers vaccinated during the recommended window had higher concentrations of pertussis antibodies at birth 9

For pregnant women due for a tetanus booster (>10 years since previous Td), Tdap should be administered between 27-36 weeks gestation 5, 11
For wound management during pregnancy, if a tetanus booster is indicated (≥5 years since previous booster), Tdap should be administered regardless of gestational age 5, 10, 12
For pregnant women with unknown or incomplete tetanus vaccination history, a series of three vaccinations is recommended (0, 4 weeks, and 6-12 months), with Tdap replacing one dose, preferably between 27-36 weeks gestation 5, 11
If Tdap is not administered during pregnancy, it should be given immediately postpartum for women who have never received it 5, 13, 12

Inactivated vaccines like Tdap are generally safe during pregnancy 12
Experience with tetanus toxoid-containing vaccines suggests no excess risk for severe adverse events for women receiving Tdap with every pregnancy 10, 14
The potential benefit of preventing pertussis morbidity and mortality in infants outweighs theoretical concerns of possible adverse events 10, 14

Missing the optimal window (27-36 weeks) for Tdap administration 12
Delaying Tdap vaccination when indicated for wound management during pregnancy 5, 10
Not administering Tdap during each pregnancy, regardless of prior vaccination history 13, 12
Failing to recognize that maternal antibodies wane quickly, making vaccination during each pregnancy necessary 5, 9